Examkin

Question

Difficulty: MediumHematology and Oncology

Match each clinical presentation of a suspected chemotherapy-induced adverse effect with the most likely responsible antineoplastic agent.

  • A 62-year-old man undergoing systemic induction therapy for advanced non-Hodgkin lymphoma presents with acute gross hematuria and suprapubic discomfort. Vitals are normal. Urinalysis reveals numerous red blood cells with no leukocyte esterase, nitrites, or bacteria.Cyclophosphamide
  • A 31-year-old man receiving curative-intent multi-agent chemotherapy for a metastatic germ cell tumor reports progressive bilateral tinnitus and high-frequency hearing loss over the past three months. Otoscopic exam is unremarkable; audiometry confirms sensorineural loss.Cisplatin
  • A 55-year-old woman on targeted maintenance therapy for HER2-positive breast cancer presents with new-onset exertional dyspnea and 2+ pitting peripheral edema. Echocardiography shows a diffuse reduction in left ventricular ejection fraction to 40% without focal wall motion abnormalities.Trastuzumab
  • A 26-year-old man treated with chemotherapy for classical Hodgkin lymphoma presents with a dry, nonproductive cough and worsening exertional dyspnea. Vitals show an oxygen saturation of 91% on room air. High-resolution CT shows bilateral basilar interstitial infiltrates and early fibrosis.Bleomycin

Answer

Cyclophosphamide matches with gross hematuria (hemorrhagic cystitis), Cisplatin matches with sensorineural hearing loss (ototoxicity), Trastuzumab matches with reduced left ventricular ejection fraction (cardiotoxicity), and Bleomycin matches with interstitial pulmonary fibrosis.
Each antineoplastic agent has a distinct side effect profile based on its pharmacologic mechanism and tissue distribution. Identifying these specific toxicities is critical in oncology practice because it dictates appropriate supportive care (such as mesna for cyclophosphamide), therapy modification, or prompt discontinuation of the offending drug.

Step-by-Step Solution

1
Evaluate the patient presenting with sterile gross hematuria during non-Hodgkin lymphoma treatment.
Identify cyclophosphamide as the likely causative agent.
Cyclophosphamide is metabolized to acrolein, which accumulates in the urine and is directly toxic to the bladder mucosa, causing hemorrhagic cystitis.
2
Evaluate the patient with high-frequency hearing loss and tinnitus during germ cell tumor treatment.
Identify cisplatin as the causative agent.
Platinum-based agents damage the outer hair cells of the organ of Corti, leading to bilateral, irreversible sensorineural hearing loss.
3
Evaluate the patient with new-onset heart failure and reduced ejection fraction during HER2-positive breast cancer treatment.
Identify trastuzumab as the causative agent.
HER2 signaling is important for cardiomyocyte survival. Trastuzumab inhibition can lead to myocardial dysfunction, which is typically not dose-dependent and often reversible upon discontinuation.
4
Evaluate the patient with dry cough, hypoxia, and bilateral interstitial infiltrates after Hodgkin lymphoma treatment.
Identify bleomycin as the causative agent.
Bleomycin causes oxidative damage to lung tissue, leading to pneumonitis and progressive pulmonary fibrosis.

Key Concept

Recognition of classic antineoplastic agent toxicity profiles.
Rate this question

Topics

Hematology and Oncology

More questions from this topic